Illinois News Desk

“Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Wet Age-Related Macular Degeneration Market. 

The Wet Age-Related Macular Degeneration Pipeline report embraces in-depth commercial, regulatory, and Wet Age-Related Macular Degeneration clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Wet Age-Related Macular Degeneration drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for Wet Age-Related Macular Degeneration treatment and the aggregate therapies developed by major pharma companies.

• It accesses the different Wet Age-Related Macular Degeneration therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the major Wet Age-Related Macular Degeneration companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the Wet Age-Related Macular Degeneration drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Wet Age-Related Macular Degeneration therapeutic market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Wet Age-Related Macular Degeneration Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide

• Peptide

• Small molecule

Learn How the Wet Age-Related Macular Degeneration Treatment Outlook will Evolve with the Ongoing Clinical & Commercial Activities in the Therapeutic Market @

https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight

Wet Age-Related Macular Degeneration (Wet AMD) Therapeutics Landscape

There are approx. 75+ key companies developing therapies for Wet Age-related Macular Degeneration. Currently, Molecular Partners is leading the therapeutics market with its Wet Age-related Macular Degeneration drug candidates in the most advanced stage of clinical development.

Wet Age-Related Macular Degeneration (Wet AMD) Companies Actively Working in the Therapeutic Market Include:

Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and many others.

Emerging and Marketed Wet Age-Related Macular Degeneration (Wet AMD) Drugs Covered in the Report Include:

• Abicipar pegol: Molecular Partners

• SOK583A1: Sandoz

• BA9101 (LY09004): Shandong Boan Biotechnology Co. Ltd.

• ADVM-022: Adverum Biotechnologies

And Many Others

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Wet Age-Related Macular Degeneration Companies Working in the Market:

https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Wet Age-Related Macular Degeneration Treatment Patterns

4. Wet Age-Related Macular Degeneration – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Wet Age-Related Macular Degeneration Late Stage Products (Phase-III)

7. Wet Age-Related Macular Degeneration Mid-Stage Products (Phase-II)

8. Wet Age-Related Macular Degeneration Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Wet Age-Related Macular Degeneration Discontinued Products

13. Wet Age-Related Macular Degeneration Product Profiles

14. Major Wet Age-Related Macular Degeneration Companies in the Market

15. Key Products in the Wet Age-Related Macular Degeneration Therapeutics Segment

16. Dormant and Discontinued Products

17. Wet Age-Related Macular Degeneration Unmet Needs

18. Wet Age-Related Macular Degeneration Future Perspectives

19. Wet Age-Related Macular Degeneration Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Amyloidosis Market

“Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Amyloidosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Amyloidosis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/